Proprietary names Antegren, Tysabri
A humanised monoclonal antibody against alpha4 integrin, which has been used to treat multiple sclerosis and Crohn’s disease.
Adverse effects Fatigue, allergic reactions, headache, nausea, colds and exacerbation of Crohn’s disease in some patients, rarely it may cause demyelination (progressive multifocal leukoencephalopathy–PML), clinically significant liver damage in 0.1% of patients.
Mechanism, PML Natalizumab inhibits alpha 4 integrin and suppresses the immune system so much it allows activation of latent JC virus.
References JAMA Neurology 2013; 70:469-475